Starpharma P/E
Cos'è P/E di Starpharma?
P/E di Starpharma Holdings Limited è N/A
Qual è la definizione di P/E?
Il rapporto prezzo / utili è il rapporto tra il prezzo delle azioni di una società e l'utile per azione della società calcolato su dodici mesi.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E di aziende nel Health Care settore su ASX rispetto a Starpharma
Cosa fa Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Aziende con p/e simili a Starpharma
- Equitorial Exploration ha P/E di N/A
- Quinto Resources ha P/E di N/A
- Melior Resources ha P/E di N/A
- Anevia SA ha P/E di N/A
- New Found Gold Corp ha P/E di N/A
- Bank of Marin Bancorp ha P/E di N/A
- Starpharma ha P/E di N/A
- National Oxygen ha P/E di N/A
- PZ Cussons Plc ha P/E di N/A
- PowerFleet Inc ha P/E di N/A
- Edvance International ha P/E di N/A
- First Vanadium ha P/E di N/A
- AltiGen Communications ha P/E di N/A